Literature DB >> 25183577

Narcotic bowel syndrome and opioid-induced constipation.

Eva Szigethy1, Marc Schwartz, Douglas Drossman.   

Abstract

Prescription opioid use for chronic non-cancer pain has reached epidemic levels in the USA. With this increased use is the recognition of serious opioid-related gastrointestinal complications such as narcotic bowel syndrome (NBS) and opioid-induced constipation (OIC). NBS consists of a paradoxical worsening of abdominal pain with escalating doses of opioids and is likely mediated by the central nervous system. Therapy requires an intensive multidisciplinary approach to detoxification. OIC is the most common gastrointestinal side effect of opioids. Several novel therapeutics are available to treat OIC that fails to respond to laxative therapy. This review will summarize recent findings on the pathophysiology and treatment approaches to NBS and OIC with a focus on controversies about diagnosis and intervention.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25183577     DOI: 10.1007/s11894-014-0410-4

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  80 in total

Review 1.  Opioid-induced bowel dysfunction.

Authors:  Gyanprakash A Ketwaroo; Vivian Cheng; Anthony Lembo
Journal:  Curr Gastroenterol Rep       Date:  2013-09

2.  Ultra-low dose ketamine and memantine treatment for pain in an opioid-tolerant oncology patient.

Authors:  Lucinda A Grande; Brendan R O'Donnell; Dermot R Fitzgibbon; Gregory W Terman
Journal:  Anesth Analg       Date:  2008-10       Impact factor: 5.108

Review 3.  Opioid epidemic in the United States.

Authors:  Laxmaiah Manchikanti; Standiford Helm; Bert Fellows; Jeffrey W Janata; Vidyasagar Pampati; Jay S Grider; Mark V Boswell
Journal:  Pain Physician       Date:  2012-07       Impact factor: 4.965

4.  Opioid utilization and health-care costs among patients with diabetic peripheral neuropathic pain treated with duloxetine vs. other therapies.

Authors:  Ning Wu; Shih-Yin Chen; Lindsay A Hallett; Luke Boulanger; Kimberly A Fraser; Chintan K Patel; Yang Zhao
Journal:  Pain Pract       Date:  2011 Jan-Feb       Impact factor: 3.183

5.  A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.

Authors:  Winfried Meissner; Petra Leyendecker; Stefan Mueller-Lissner; Joachim Nadstawek; Michael Hopp; Christian Ruckes; Stefan Wirz; Wolfgang Fleischer; Karen Reimer
Journal:  Eur J Pain       Date:  2008-08-31       Impact factor: 3.931

Review 6.  Central pain mechanisms in the rheumatic diseases: future directions.

Authors:  Kristine Phillips; Daniel J Clauw
Journal:  Arthritis Rheum       Date:  2013-02

7.  A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia.

Authors:  Lesley M Arnold; I Jon Russell; E W Diri; W Rachel Duan; James P Young; Uma Sharma; Susan A Martin; Jeannette A Barrett; George Haig
Journal:  J Pain       Date:  2008-06-03       Impact factor: 5.820

8.  Opioid bowel dysfunction and narcotic bowel syndrome: a population-based study.

Authors:  Rok Seon Choung; G Richard Locke; Alan R Zinsmeister; Cathy D Schleck; Nicholas J Talley
Journal:  Am J Gastroenterol       Date:  2009-04-14       Impact factor: 10.864

9.  Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.

Authors:  Craig Hartrick; Ilse Van Hove; Jens-Ulrich Stegmann; Charles Oh; David Upmalis
Journal:  Clin Ther       Date:  2009-02       Impact factor: 3.393

Review 10.  Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward.

Authors:  Mark R Hutchinson; Sondra T Bland; Kirk W Johnson; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  ScientificWorldJournal       Date:  2007-11-02
View more
  12 in total

Review 1.  Management of pain in chronic pancreatitis with emphasis on exogenous pancreatic enzymes.

Authors:  Paul M Hobbs; William G Johnson; David Y Graham
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-08-06

Review 2.  Opioid misuse in gastroenterology and non-opioid management of abdominal pain.

Authors:  Eva Szigethy; Mitchell Knisely; Douglas Drossman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-11-15       Impact factor: 46.802

Review 3.  Novel transmitters in brain stem vagal neurocircuitry: new players on the pitch.

Authors:  Mehmet Bülbül; R Alberto Travagli
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-03-29       Impact factor: 4.052

4.  High-Dose Opioid Use Among Veterans with Unexplained Gastrointestinal Symptoms Versus Structural Gastrointestinal Diagnoses.

Authors:  Salva N Balbale; Lishan Cao; Itishree Trivedi; Jonah J Stulberg; Katie J Suda; Walid F Gellad; Charlesnika T Evans; Bruce L Lambert; Neil Jordan; Laurie A Keefer
Journal:  Dig Dis Sci       Date:  2021-01-01       Impact factor: 3.199

5.  Pain Management in Chronic Pancreatitis: Summary of Clinical Practice, Current Challenges and Potential Contribution of the M-ANNHEIM Classification.

Authors:  Alexander Schneider; Michael Hirth
Journal:  Drugs       Date:  2021-02-15       Impact factor: 9.546

6.  Opioid-related emergency department visits and hospitalizations among patients with chronic gastrointestinal symptoms and disorders dually enrolled in the Department of Veterans Affairs and Medicare Part D.

Authors:  Salva N Balbale; Lishan Cao; Itishree Trivedi; Jonah J Stulberg; Katie J Suda; Walid F Gellad; Charlesnika T Evans; Neil Jordan; Laurie A Keefer; Bruce L Lambert
Journal:  Am J Health Syst Pharm       Date:  2022-01-05       Impact factor: 2.980

Review 7.  New developments in the treatment of opioid-induced gastrointestinal symptoms.

Authors:  Jasper Pannemans; Tim Vanuytsel; Jan Tack
Journal:  United European Gastroenterol J       Date:  2018-08-27       Impact factor: 4.623

Review 8.  Insights into the Use of Peripherally Acting μ-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice.

Authors:  Ana Fernández-Montes; Guillermo de Velasco; Santiago Aguín; Cristina Farriols; María Guirado-Risueño; Vanessa G Jerviz-Guía; María Victoria Baeza-Nadal; Rodolfo Chicas-Sett; José Luis Fírvida; Francisco García-Navalón; Patricia Martín; Carmen Perezagua-Marín; Dulce Rodríguez; Joan Santamaría; Tamara Saurí; Manuel Cobo
Journal:  Curr Treat Options Oncol       Date:  2021-02-26

9.  An opioid receptor-independent mechanism underlies motility dysfunction and visceral hyperalgesia in opioid-induced bowel dysfunction.

Authors:  You-Min Lin; Yanbo Tang; Yu Fu; Shrilakshmi Hegde; Daniel W Shi; Li-Yen M Huang; Xuan-Zheng Shi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2021-04-28       Impact factor: 4.871

10.  Characteristics of Opioid Prescriptions to Veterans With Chronic Gastrointestinal Symptoms and Disorders Dually Enrolled in the Department of Veterans Affairs and Medicare Part D.

Authors:  Salva N Balbale; Lishan Cao; Itishree Trivedi; Jonah J Stulberg; Katie J Suda; Walid F Gellad; Charlesnika T Evans; Bruce L Lambert; Laurie A Keefer; Neil Jordan
Journal:  Mil Med       Date:  2021-08-28       Impact factor: 1.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.